AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Mar 2017 02:30 PM
RNS
Annual Financial Report
06 Mar 2017 07:00 AM
RNS
Directorate Change
03 Mar 2017 07:00 AM
RNS
ALLIANCE WITH SANOFI PASTEUR FOR MEDI8897
01 Mar 2017 04:30 PM
RNS
Total Voting Rights
28 Feb 2017 07:02 AM
RNS
FDA approves once-daily Qtern for type-2 diabetes
24 Feb 2017 12:32 PM
RNS
CHMP positive opinion for ZS-9 in hyperkalaemia
20 Feb 2017 07:00 AM
RNS
AZ licenses Zoladex to TerSera for the US & Canada
17 Feb 2017 07:00 AM
RNS
Lynparza positive in metastatic BRCA breast cancer
16 Feb 2017 12:01 PM
RNS
SILIQ (BRODALUMAB) APPROVED BY US FDA
02 Feb 2017 07:00 AM
RNS
AZN: FY16 and Q4 2016 Results
01 Feb 2017 04:00 PM
RNS
Total Voting Rights
26 Jan 2017 10:00 AM
RNS
SYMBICORT GRANTED PAEDIATRIC EXCLUSIVITY IN THE US
17 Jan 2017 07:00 AM
RNS
AZ 1st-line lung cancer immuno-oncology programme
03 Jan 2017 04:00 PM
RNS
Total Voting Rights
23 Dec 2016 07:00 AM
RNS
AZ COMPLETES SALE OF ANTIBIOTICS BUSINESS
16 Dec 2016 01:00 PM
RNS
Director/PDMR Shareholding
09 Dec 2016 03:05 PM
RNS
FDA accepts durvalumab for BLA in bladder cancer
06 Dec 2016 09:30 AM
RNS
Tagrisso data shows superiority over chemotherapy
05 Dec 2016 07:00 AM
RNS
AZ completes agreement for Rhinocort Aqua rights
01 Dec 2016 04:00 PM
RNS
Block listing Interim Review
01 Dec 2016 03:00 PM
RNS
Total Voting Rights
22 Nov 2016 07:00 AM
RNS
AZ head and neck cancer trials resume enrolment
17 Nov 2016 07:00 AM
RNS
AZ out-licensing deal with Allergan completed
10 Nov 2016 07:04 AM
RNS
Year-To-Date and Q3 2016 Results
09 Nov 2016 07:00 AM
RNS
Directorate Change
01 Nov 2016 03:30 PM
RNS
Dealing by Person Closely Associated
01 Nov 2016 03:00 PM
RNS
Total Voting Rights
31 Oct 2016 01:47 PM
RNS
AZ completes US Aralez agreement for Toprol-XL
27 Oct 2016 04:51 PM
RNS
AstraZeneca Head and Neck Cancer Trials
26 Oct 2016 07:00 AM
RNS
Positive results in AstraZeneca Lynparza trial
18 Oct 2016 07:00 AM
RNS
FDA accepts for review ZS-9 NDA for hyperkalaemia
07 Oct 2016 07:00 AM
RNS
AZ DIVESTS RIGHTS TO RHINOCORT AQUA OUTSIDE US
04 Oct 2016 07:05 AM
RNS
AZ agreement with Aralez for Toprol-XL in US
04 Oct 2016 07:00 AM
RNS
AstraZeneca reports top-line EUCLID results in PAD
03 Oct 2016 03:00 PM
RNS
Total Voting Rights
03 Oct 2016 07:00 AM
RNS
MedImmune out-licenses medicine to Allergan
28 Sep 2016 07:00 AM
RNS
CHANGE TO ASTRAZENECA BOARD OF DIRECTORS
26 Sep 2016 04:00 PM
RNS
Director/PDMR Shareholding
22 Sep 2016 11:00 AM
RNS
Director Declaration
01 Sep 2016 02:30 PM
RNS
Total Voting Rights
01 Sep 2016 07:00 AM
RNS
AstraZeneca Completes Aspen Agreement
24 Aug 2016 07:00 AM
RNS
AZ TO SELL ANTIBIOTICS BUSINESS TO PFIZER
18 Aug 2016 01:00 PM
RNS
Director Declaration
16 Aug 2016 07:00 AM
RNS
AstraZeneca completes agreement with LEO Pharma
10 Aug 2016 02:41 PM
RNS
ASTRAZENECA ANNOUNCES INVESTMENT IN MODERNA
09 Aug 2016 07:00 AM
RNS
ASTRAZENECA UPDATE ON SELUMETINIB PHASE III TRIAL
01 Aug 2016 02:30 PM
RNS
Total Voting Rights
01 Aug 2016 11:00 AM
RNS
Director/PDMR Shareholding
28 Jul 2016 07:00 AM
RNS
AZN: H1 2016 Results
27 Jul 2016 09:00 AM
RNS
Notice of Results

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England.

It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It was involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

Astra Zeneca share price launched at 605p in 1993.

UK 100

Latest directors dealings